Technical Analysis for HGEN - Humanigen, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.00 | -84.62% | 0.00 |
Earnings due: Mar 28
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Very Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 20 DMA | Bearish | 0.00% | |
Fell Below 50 DMA | Bearish | 0.00% | |
Volume Surge | Other | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Gapped Down | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Crossed Above 20 DMA | Bullish | -84.62% | |
Volume Surge | Other | -84.62% | |
Calm After Storm | Range Contraction | -84.62% |
Free Daily (Stock) Chart Reading
- Earnings date: 03/28/2024
Humanigen, Inc. Description
Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The company's immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Clinical Medicine Immune System Immunotherapy Infectious Diseases Treatment Of Cancer Lymphoma Gene Therapy Infection Coronavirus Dysfunction Transplantation Chimeric Antigen Receptor T Cell Cytokine Hematopoietic Stem Cell Platform Technologies Host Disease Gilead Sciences Graft Versus Host Disease Eosinophil Coronavirus Infection Cytokine Release Syndrome Solid Cancers
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 0.239 |
52 Week Low | 0.0001 |
Average Volume | 279,236 |
200-Day Moving Average | 0.07 |
50-Day Moving Average | 0.00 |
20-Day Moving Average | 0.00 |
10-Day Moving Average | 0.00 |
Average True Range | 0.00 |
RSI (14) | 47.09 |
ADX | 51.15 |
+DI | 40.14 |
-DI | 16.90 |
Chandelier Exit (Long, 3 ATRs) | 0.00 |
Chandelier Exit (Short, 3 ATRs) | 0.00 |
Upper Bollinger Bands | 0.00 |
Lower Bollinger Band | 0.00 |
Percent B (%b) | 0.14 |
BandWidth | 220.00 |
MACD Line | 0.00 |
MACD Signal Line | 0.00 |
MACD Histogram | 0.0001 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.00 | ||||
Resistance 3 (R3) | 0.00 | 0.00 | 0.00 | ||
Resistance 2 (R2) | 0.00 | 0.00 | 0.00 | 0.00 | |
Resistance 1 (R1) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pivot Point | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Support 1 (S1) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Support 2 (S2) | 0.00 | 0.00 | 0.00 | 0.00 | |
Support 3 (S3) | 0.00 | 0.00 | 0.00 | ||
Support 4 (S4) | 0.00 |